CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 201 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Hydrocortisone 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04924166
NCT04924166Phase 2Completed

PTSD Prevention Using Oral Hydrocortisone in the Immediate Aftermath of Trauma

Rachel Yehuda·interventional·Posted Jun 11, 2021·Updated Mar 19, 2026

In Brief

A Phase 2 clinical trial evaluating Placebo and Hydrocortisone for PTSD and 2 related conditions. Completed, enrolled 201 participants across 3 sites in 2 countries.

Detailed Summary

There is currently no evidence-based intervention for individuals exposed to trauma that is designed to aid recovery and prevent the development of post-traumatic stress disorder (PTSD). This randomized control trial proposes to test a one-time prophylactic treatment for the prevention of symptoms of PTSD and related mental health disturbances and the promotion of resilience using a single dose of hydrocortisone (HCORT) or placebo, administered within six hours of trauma exposure. People at risk for PTSD have demonstrated low cortisol levels before and in the aftermath of traumatic exposures and lower cortisol levels have also been observed in combat veterans with PTSD. Administering HCORT at the time of trauma would help boost the body's natural stress recovery systems to facilitate resilience. Participants who present to the emergency department following trauma exposure and report high distress, panic, anxiety or dissociation will be invited to participate in this clinical trial. 220 trauma survivors will be randomized and recruited at two locations: Mount Sinai Hospital in New York City, US, and a civilian/military hospital in Tel Hashomer, Israel. Trauma survivors will be assessed at 2, 6, 12 and 28 weeks post-treatment. HCORT closely resembles cortisol produced in the adrenal glands and released during stress. It is hypothesized that HCORT treatment will result in an accelerated decline in the presence and severity of PTSD and related mental health symptoms compared to the placebo group. Blood samples will be collected for analysis of potential biomarkers to obtain more information about the mechanisms of action of this intervention. The information obtained will be relevant in determining whether early intervention with a single dose of HCORT, compared to placebo, administered within several hours following trauma exposure, will reduce the risk of developing PTSD in trauma survivors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael, United States

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJun 11, 2021
Enrollment StartJan 12, 2022
Primary CompletionJul 6, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.1 years ago

Interventions

Placebodrug

Inactive dose of capsules that appear identical to active dose

Hydrocortisonedrug

Hydrocortisone 180 mg in capsule form